Hematology/Oncology

Top Story

Vitamin K antagonists do not affect bone mineral density, fracture risk

September 2, 2015

Vitamin K antagonists do not increase the risk for fracture or reduce bone mineral density, according to findings published in the Journal of Thrombosis and Haemostasis.

“Because osteocalcin, a protein produced by osteoblasts, undergoes the same carboxylation process [as vitamin K], the inhibition of the gamma-carboxylation exerted by vitamin K antagonists leads to lower incorporation in the bone matrix,” the researchers write. “Undercarboxylated osteolcalcin serum levels increase with the use of vitamin K antagonists, but whether this translates into fracture risk or lower bone mineral density values is still controversial.”

Worth Building

Back-to-school reminder for parents and students: Check out college tax credits

September 2, 2015
With another school year here, the Internal Revenue Service reminds parents and students that now is a good time to see if they will qualify for either of two college…
FDA News

FDA approves Varubi for chemotherapy-induced nausea, vomiting

September 2, 2015
The FDA today approved rolapitant for the treatment of delayed-phase nausea and vomiting in patients with cancer who are undergoing chemotherapy.Rolapitant (Varubi…
In the Journals

Histologic regression may predict SLNB benefit in melanoma

September 2, 2015
Sentinel lymph node positivity occurred less frequently in patients with primary melanoma who had histologic regression, according to the results of a systemic review…
Meenakshi Bewtra In the Journals

Radiofrequency ablation reduces neoplastic progression in Barrett's esophagus

September 2, 2015
Patients with Barrett’s esophagus and confirmed low-grade dysplasia who underwent radiofrequency ablation had lower rates of neoplastic progression, according to…
More News Headlines »
CME
Hematology Oncology Case Consults

The Patient with Invasive Breast Cancer

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with invasive breast cancer.
More »
Meeting News Coverage Video
VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

August 20, 2015
CHICAGO — The PALOMA-3 trial, which evaluated the addition of palbociclib to fulvestrant, demonstrated…
More »
CME
Immunotherapy Updates 2015: FOCUS on NSCLC

Immunotherapy Updates 2015: FOCUS on NSCLC

This activity is supported by educational grants from Genentech, Inc. and Merck & Co., Inc.

Globally, lung cancer is the leading cause of cancer-related deaths. Non-small cell lung cancer (NSCLC) accounts for…
More »
morganatic-roan morganatic-roan